COMMUNIQUÉS West-GlobeNewswire

Route 92 Medical Celebrates the 200th Patent for its Neurovascular Intervention Portfolio
20/07/2026
New global patents protect Route 92 Medical’s ongoing innovation as the company works to address critical unmet needs in neurovascular treatment WEST JORDAN, Utah, July 20, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc [...]
La Cour suprême du Canada confirme l’interdiction des brevets sur les traitements médicaux
20/07/2026
MONTRÉAL, 20 juill. 2026 (GLOBE NEWSWIRE) -- La Cour suprême du Canada a rendu sa décision très attendue dans l’affaire Pharmascience Inc. c. Janssen Inc. , qui porte sur la validité du brevet de Janssen relatif au [...]
Supreme Court of Canada Upholds Prohibition on Medical Treatment Patents
20/07/2026
MONTREAL, July 20, 2026 (GLOBE NEWSWIRE) -- The Supreme Court of Canada released its highly anticipated decision in Pharmascience Inc. v. Janssen Inc. , which addresses the validity of Janssen’s patent relating to the [...]
Conceivable Life Sciences Strengthens Senior Leadership Team to Support IVI RMA Partnership and U.S. Launch
20/07/2026
Julie O'Shaughnessy named President, Vincent Payet named SVP of Clinical Operations & Partner Success to support AURA's US commercial launch NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Conceivable Life Sciences, the [...]
Meliora Healthcare Welcomes Dr. Scott Thompson
20/07/2026
NAPLES, Fla., July 20, 2026 (GLOBE NEWSWIRE) -- Meliora Healthcare is pleased to announce that Board-certified orthopedic surgeon Scott Thompson, MD has joined the practice’s care team and is now accepting new patients [...]
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
20/07/2026
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease type 1, having met the primary efficacy endpoint, reduction in lesion growth Presentation to include positive update [...]
CurePSP Awards Record Pathway and Pipeline Grants to Advance PSP and CBD Research
20/07/2026
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- CurePSP has announced its largest grant cycle to date, awarding a record number of Pathway and Pipeline Grants to researchers across North America and Europe. The grants [...]
Positron Secures Multiple PET-CT Orders Amid Accelerating Shift to Cardiac PET
20/07/2026
BUFFALO, NY, July 20, 2026 (GLOBE NEWSWIRE) -- Positron Corporation ("Positron" or the "Company") (OTC: POSC), a leader in advanced molecular imaging technology and comprehensive PET imaging solutions, today announced [...]
TOMI Environmental and Carbonium Core Positioned To Play Key Role in The Onshoring of Essential Strategic Materials for Defense and Global Disinfection
20/07/2026
FREDERICK, Md., July 20, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) (“TOMI”), the leader in decontamination equipment and services with its patented SteraMist ionized Hydrogen Peroxide ( [...]
Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities
20/07/2026
President & CEO, Sabrina Martucci Johnson, to host interactive investor webcasts featuring corporate updates, commercial strategy and live Q&A SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. ( [...]
Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
20/07/2026
Designation supports development in an estimated $1 billion market where there are no FDA-approved therapies for patients whose disease progresses following first-line standard of care therapy Third Fast Track [...]
Applied Biologics Announces Submission of XWRAP® Translational Research Abstract for Consideration at SAWC Fall 2026
20/07/2026
SCOTTSDALE, Ariz., July 20, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced [...]
Xanamem proof-of-concept trial demonstrating anti-depressant activity published in the British Journal of Psychiatry
20/07/2026
Ongoing Xanamem (emestedastat) Alzheimer’s disease pivotal trial progresses toward final results in November this year SYDNEY, July 20, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) today announces that [...]
Novo Nordisk A/S - share repurchase programme
20/07/2026
Bagsværd, Denmark, 20 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
University of Szeged Pioneers First Robotic Cardiology Program in Hungary
20/07/2026
First Robotic Magnetic Navigation system installed in Hungary University of Szeged, led by Cardiology Chief Dr. Szili-Torok, expected to treat hundreds of patients annually with all forms of cardiac arrhythmia using [...]
DLH to Announce Fiscal 2026 Third Quarter Financial Results
20/07/2026
ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital [...]
Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston
20/07/2026
New headquarters reflects Collegium's long-term vision and commitment to Massachusetts STOUGHTON, Mass., July 20, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) a leading biopharmaceutical [...]
Noom Launches 'Lose for Keeps' with Rebel Wilson, a New Campaign Making the Case That GLP-1 Medication and Healthy Habits Work Better Together
20/07/2026
PRINCETON, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Noom, the leading behavior change company, launched Lose for Keeps – a new integrated brand campaign featuring Rebel Wilson in her second year as the company’s Chief [...]
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
20/07/2026
- Continued low early termination rate (4.5%) among the first 200 patients enrolled in the study suggests Halneuron® and placebo treatment have been well tolerated - ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Dogwood [...]

Pages